Could psychedelic drugs be good medicine for some?

September 8, 2015 by Alan Mozes, Healthday Reporter,
Could psychedelic drugs be good medicine for some?
Preliminary research suggests potential benefits for psychiatric disorders, substance abuse.

(HealthDay)—In a carefully controlled setting, psychedelic drugs such as LSD or "magic mushrooms" may benefit patients with hard-to-treat anxiety, addiction or post-traumatic stress disorder (PTSD), new research suggests.

The finding comes from a review of small-scale and preliminary studies conducted recently in the United States, Canada and Europe, all of which await follow-up.

These preliminary results show that "in the right context, these drugs can help people a lot, especially people who have disorders that we generally treat poorly, such as end-of-life distress, PTSD, and addiction issues involving tobacco or alcohol," said study co-author Matthew Johnson. Johnson is an associate professor in the department of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine in Baltimore.

The research Johnson and his colleagues point to includes a 2008 study that found that psilocybin-assisted psychotherapy resulted in lower anxiety and improved mood, without negative side effects. Psilocybin is the hallucinogenic compound in "magic mushrooms."

And a Swiss study published last year looked at LSD's effect on terminally ill patients who were battling anxiety. Two months after two LSD-enhanced psychotherapy sessions, the patients experienced "significant" reductions in some forms of anxiety, a benefit that endured one year out, without long-lasting side effects.

Despite these findings, Johnson cautioned, "people should not go out on their own to treat themselves with these drugs. These drugs need to be researched according to a strict regulatory process, the same as you would develop any drug."

The notion that "street drugs" might successfully treat serious mental illness flies in the face of the widely held perception that psychedelics are dangerous. It also represents a dramatic turnaround from earlier research—much of it conducted in the counter-culture heyday of the 1960s—that was largely discredited by the medical community.

Besides LSD and psilocybin, the drugs examined in the new review included mescaline; DMT, the common name for the hallucinogenic drug dimethyltryptamine; and the mood-elevating drug MDMA, or methylenedioxy-methamphetamine, also known as Ecstasy or Molly.

This fresh look at psychedelics should be viewed as an attempt to "further our understanding of how the brain works," suggested Dr. Jeffrey Borenstein, president of the Brain & Behavior Research Foundation in New York City. Borenstein wasn't involved in the research.

"We certainly have to be careful," he said. "Some of these drugs clearly have the potential for misuse and addiction. But there may be aspects that perhaps have a potential benefit, particularly if we could find a way to isolate their helpful mechanisms of action."

For example, this might mean finding a way to separate and deploy a drug's therapeutic antidepressant effect, without the negative impact of, say, dislocation or hallucination, he said.

"To my mind, if working with these agents can lead to new approaches to treat serious conditions, that is all to the good," Borenstein added. "While we currently have some effective methods of treatment for a number of these conditions, we are always looking for improvement."

The findings are published in the Sept. 8 issue of CMAJ (Canadian Medical Association Journal).

Other studies mentioned in the review include one that found that psilocybin helped 12 out of 15 smokers kick their tobacco habit by the six-month post-treatment mark.

In another, more than 80 percent of PTSD patients who underwent two-sessions of psychotherapy coupled with MDMA experienced a more than 30 percent drop in the severity of their symptoms, compared with 25 percent of those who didn't take MDMA. The benefits held up for nearly three-quarters of the patients three and half years out.

And researchers studying alcoholism in New Mexico found that coupling "motivational enhancement therapy" with magic mushrooms halved heavy drinking without any significant or long-lasting side effects.

"The biological and psychological evidence seems to show that these drugs can have a unique effect on altering the patient's subjective experience in a very powerful and meaningful way," said Johnson. He added the drugs "can help people who are in a very difficult place psychologically break out and get unstuck."

However, he added, "these are experiences that happen in a psycho-therapeutic context, which is critical to increasing the chances for a life-changing positive experience without any long-term harmful effects."

Explore further: More research needed on benefits of psychedelic drugs

More information: CMAJ, www.cmaj.ca/lookup/doi/10.1503/cmaj.141124

Related Stories

More research needed on benefits of psychedelic drugs

October 9, 2014
A University of Adelaide philosophy scholar is calling for more research into the therapeutic benefits of psychedelic drugs, with early studies suggesting these substances can provide lasting psychological benefits.

Psychedelic drugs should be legally reclassified as they may benefit patients, psychiatrist says

May 26, 2015
Legal restrictions imposed on medical use of psychedelic drugs, such as LSD and psilocybin (the compound found in 'magic' mushrooms), are making trials almost impossible and authorities should 'downgrade their unnecessarily ...

Use of psychedelic drugs remains prevalent in the US

April 23, 2013
An article published in F1000Research, and approved for indexing in PubMed and other major bibliographical databases, estimates that there were approximately 32 million users of psychedelic drugs in the United States in 2010.

LSD, other psychedelics not linked with mental health problems in new study

August 19, 2013
The use of LSD, magic mushrooms, or peyote does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 130,000 randomly chosen people, including 22,000 people ...

No link between psychedelics and mental health problems

March 5, 2015
The use of psychedelics, such as LSD and magic mushrooms, does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 135,000 randomly chosen people, including ...

Benzodiazepines not recommended for patients with PTSD or recent trauma

July 14, 2015
Benzodiazepine drugs are widely used in patients with posttraumatic stress disorder (PTSD), but available evidence suggests that they are not effective—and may even be harmful, concludes a systematic review and meta-analysis ...

Recommended for you

Researchers identify brain mechanism linking PTSD and opioid addiction

April 23, 2018
Researchers at Western University have shown that the recall of traumatic memories enhances the rewarding effects of morphine, shedding light on the neurobiological link between post-traumatic stress disorder (PTSD) and opioid ...

Scientific guidelines for using cannabis to treat stress, anxiety and depression

April 19, 2018
In a first-of-a-kind study, Washington State University scientists examined how peoples' self-reported levels of stress, anxiety and depression were affected by smoking different strains and quantities of cannabis at home.

Neuroscientists use magnetic stimulation to amplify PTSD therapy

April 19, 2018
Researchers from The University of Texas at Dallas have found that a standard therapy for post-traumatic stress disorder (PTSD) is more effective when paired with transcranial magnetic stimulation of the brain.

Research reveals stronger people have healthier brains

April 19, 2018
A study of nearly half a million people has revealed that muscular strength, measured by handgrip, is an indication of how healthy our brains are.

Study suggests we can recognize speakers only from how faces move when talking

April 18, 2018
Results of a new study by cognitive psychologist and speech scientist Alexandra Jesse and her linguistics undergraduate student Michael Bartoli at the University of Massachusetts Amherst should help to settle a long-standing ...

Scientists disconfirm belief that humans' physiological reaction to emotions are uniform

April 18, 2018
How do you feel when you're angry? Tense? Jittery? Exhausted? Is it the same every time? Is it identical to how your best friend, co-worker, or barista feel when they experience anger? In all likelihood the answer is no, ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

RMQ
4 / 5 (1) Sep 08, 2015
Psychedelics will be an alternative if big pharmaceutical companies make money of them. Because pharmaceutical companies obviously write the laws and enforce them.
trxtgreen
5 / 5 (1) Sep 08, 2015
"We certainly have to be careful," he said. "Some of these drugs clearly have the potential for misuse and addiction."

Ummm no. Ecstasy is addictive, but psilocybin mushrooms, LSD, and DMT are some of the least addictive psychoactive drugs on the planet. I think it's probably impossible to get addicted to mushrooms-- they simply won't work if you take them repeatedly in a week.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.